PracticeUpdate: Haematology & Oncology

VOL. 1 • No. 4 • 2016

RESEARCH NEWS AND VIEWS FROM ELSEVIER

FORMERLY HAEMATOLOGY & ONCOLOGY NEWS

Readers Poll What’s the ONE medical app you can’t live without?

Postmastectomy radiation improved local control but not overall survival in women with breast cancer

Scan this code or go to goo.gl/68Uauc to have your say in this issue’s PracticeUpdate Haematology & Oncology Readers Poll.

OPINION

If I had to placemy chip 50 years down the future onwhat wewould know, I’d say it’s probably going to turn out to be viruses that we’re exposed too. They often end up integrating into our genome, unbeknownst to us. Dr Steven Toms 15

PROSTATE Special roundup of the 17th APCC in Melbourne

Patients treated with modern systemic therapy experienced excellent outcomes in local control and overall survival, regardless of whether they received radiation therapy.

4

CONFERENCE ASTRO 2016 A radiation boost is

10

recommended in patients with DCIS and ≥10 years life expectancy following breast-conserving surgery and whole breast radiotherapy Reduced radiation boost volume is recommended but craniospinal axis dose remains unchanged in average-risk paediatric medulloblastoma After 10 years, postmastectomy radiation is shown to improve local control but not overall survival in women with breast cancer and one to three positive nodes 10 FEATURE ARTICLE MicroRNAs in brain cancer treatment 15 8 9

Risk of neutropenia-related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer Journal of Clinical Oncology There was a low to modest benefit relative to neutropenia- related hospitalizations associated with G-CSF prophylaxis in breast cancer patients being treated with TC and TCH.

Dual block with lapatinib and trastuzumab vs single-agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials Clinical Cancer Research Patients with HER2-positive breast cancer benefit from the neoadjuvant combination of lapatinib and trastuzumab, while hormone receptor- negative patients demonstrate the best results with taxane monotherapy. 5

Daratumumab, bortezomib, and dexamethasone for multiple myeloma The New England Journal of Medicine Daratumumab with bortezomib and dexamethasone led to significantly increased

Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group Trials, 1980–2008 Journal of Clinical Oncology EMD is relatively common, but not an independent prognostic factor in AML. They suggest that AML treatment decisions should be based on the presence of recognized AML prognostic factors, and not on the presence of EMD. 14

progression-free survival, but also resulted in more frequent adverse events compared with bortezomib/ dexamethasone alone.

5

13

Made with